What Are Circulating Tumor Cells and Why Do They Matter?

Circulating tumor cells (CTCs) are cancer cells that have detached from a primary tumor and entered the bloodstream. These cells are detectable in blood samples and are a key focus of cancer research. The study of CTCs aims to identify cancer presence, monitor treatment effectiveness, and gain insights into disease progression.

Understanding Circulating Tumor Cells

Circulating tumor cells originate from primary tumors and enter the bloodstream or lymphatic system, a process known as intravasation. These cells travel through the body’s circulatory system, potentially establishing new tumors in other organs, a process called metastasis.

Metastasis is responsible for over 90% of cancer-related deaths, underscoring the significance of CTCs. CTCs are exceptionally rare in peripheral blood; for instance, approximately one CTC might be found among ten million white blood cells. This scarcity makes their detection and analysis particularly challenging.

CTCs exhibit considerable heterogeneity, displaying diverse molecular markers and physical characteristics. This diversity reflects the original tumor’s nature and influences their ability to survive in the bloodstream and initiate new growths. Only a small fraction of these circulating cells successfully forms secondary tumors.

CTCs adapt and survive in the harsh blood microenvironment through interactions with blood components and evasion of immune detection. Some CTCs can form clusters, which may increase their metastatic potential and are associated with a poorer patient outlook.

Methods for Isolating Circulating Tumor Cells

Isolating circulating tumor cells from blood samples is challenging due to their rarity and fragile nature, which can lead to cell damage or loss. Various methods have been developed, broadly categorized into immunoaffinity and physical property-based approaches. Isolation techniques must be sensitive enough to capture these rare, diverse cells while effectively separating them from abundant blood cells.

Immunoaffinity techniques leverage specific antibody binding to target antigens on CTC surfaces. A common approach uses magnetic beads coated with antibodies, such as those targeting epithelial cell adhesion molecule (EpCAM), a protein often found on tumor cells. These beads selectively attach to CTCs, allowing separation from other blood components or depletion of unwanted white blood cells.

Physical property-based techniques exploit differences in characteristics like cell size, density, deformability, and electrical properties between CTCs and normal blood cells. Microfluidic devices, tiny channels designed to manipulate fluids at a microscopic level, are often used to filter or separate cells based on these physical differences.

Isolation challenges include maintaining cell viability, preventing white blood cell contamination, and ensuring the process does not alter CTCs, which could affect subsequent analysis. Many methods aim for “label-free” isolation, avoiding antibodies or other labels to minimize cell loss and potential damage. The goal is to develop repeatable, reliable, and cost-effective methods capable of processing clinically relevant blood volumes.

Analyzing Circulating Tumor Cells

Once isolated, various analytical methods extract valuable information about CTCs.

Immunophenotyping

Immunophenotyping identifies and characterizes CTCs based on specific proteins expressed on their surface or within the cell. Fluorescently labeled antibodies bind to particular markers, allowing categorization and assessment of CTC heterogeneity.

Fluorescence In Situ Hybridization (FISH)

FISH detects specific genetic alterations within CTCs using fluorescent probes that bind to particular DNA sequences on chromosomes. FISH can identify changes like gene copy number alterations (too many or too few copies of a gene) and translocations (where parts of chromosomes have swapped positions). For example, FISH has been used to determine ALK gene translocation status in non-small-cell lung cancer cells.

Polymerase Chain Reaction (PCR) and DNA Sequencing

PCR and DNA sequencing are molecular methods providing detailed genetic information from CTCs. PCR amplifies tiny amounts of DNA to detect specific oncogenic mutations (gene changes that can lead to cancer). DNA sequencing allows comprehensive genomic analysis to identify a broader range of mutations and understand the tumor cells’ genetic makeup.

Gene Expression Analysis

Gene expression analysis investigates which genes are active or “expressed” in CTCs. This analysis, though technically demanding due to mRNA’s fragile nature, offers insights into the specific biological pathways active in the tumor. It can reveal tumor-specific markers and potentially detect gene translocations or alternative splice variants, providing a more dynamic view of tumor biology.

Clinical Applications of Circulating Tumor Cells

Circulating tumor cells are promising biomarkers in cancer management, offering a less invasive alternative to traditional tissue biopsies. Their analysis provides real-time insights into the disease state, complementing existing diagnostic tools.

Cancer Diagnosis

CTCs show potential in aiding cancer diagnosis, particularly for early detection. Their presence can indicate a tumor’s existence before it is detectable by imaging. Studies are exploring their use in screening and identifying at-risk patients, though widespread clinical validation is ongoing.

Prognosis

The number of detectable CTCs at diagnosis has been linked to reduced progression-free and overall survival in various solid cancers, including breast, prostate, and colorectal cancers. A higher CTC count often correlates with increased mortality, providing valuable information for predicting disease outcomes.

Treatment Monitoring

CTCs are investigated for monitoring cancer treatment effectiveness. Tracking changes in CTC counts over time allows clinicians to assess treatment response. A decrease in CTC numbers after anti-tumor treatment can indicate a positive response, potentially guiding treatment adjustments. This allows for real-time assessment of treatment efficacy.

Drug Development and Selection

CTC analysis can guide drug development and selection by identifying specific molecular targets. Analyzing CTC genetic and protein profiles can reveal mutations or protein expressions that make a tumor susceptible or resistant to certain drugs. This supports personalized medicine, tailoring treatments to a patient’s specific tumor characteristics.

Clinical Decision Making: Key Factors and Collaborations

What Is Cardiac Depression? Symptoms & Treatments

What Are Intranuclear Inclusions and Their Causes?